Literature DB >> 12011302

Absence of elevated anti-alpha-synuclein and anti-EBV latent membrane protein antibodies in PD.

J M Woulfe1, R Duke, J M Middeldorp, S Stevens, M Vervoort, M Hashimoto, E Masliah, P Chan, D A Di Monte, J W Langston, G Petzinger, H Hoogendoorn, D G Munoz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12011302     DOI： 10.1212/wnl.58.9.1435

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  14 in total

1.  Measurements of auto-antibodies to α-synuclein in the serum and cerebral spinal fluids of patients with Parkinson's disease.

Authors:  Rizwan S Akhtar; Joseph P Licata; Kelvin C Luk; Leslie M Shaw; John Q Trojanowski; Virginia M-Y Lee
Journal:  J Neurochem       Date:  2018-06-10       Impact factor: 5.372

2.  Altered serum IgG levels to α-synuclein in dementia with Lewy bodies and Alzheimer's disease.

Authors:  Niklas K U Koehler; Elke Stransky; Mona Shing; Susanne Gaertner; Mirjam Meyer; Brigitte Schreitmüller; Thomas Leyhe; Christoph Laske; Walter Maetzler; Phillipp Kahle; Maria S Celej; Thomas M Jovin; Andreas J Fallgatter; Anil Batra; Gerhard Buchkremer; Klaus Schott; Elke Richartz-Salzburger
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

3.  Naturally occurring alpha-synuclein autoantibodies in Parkinson's disease: sources of (error) variance in biomarker assays.

Authors:  Sebastian Heinzel; Maike Gold; Christian Deuschle; Felix Bernhard; Walter Maetzler; Daniela Berg; Richard Dodel
Journal:  PLoS One       Date:  2014-12-03       Impact factor: 3.240

4.  Decrease in plasma levels of α-synuclein is evident in patients with Parkinson's disease after elimination of heterophilic antibody interference.

Authors:  Ryotaro Ishii; Takahiko Tokuda; Harutsugu Tatebe; Takuma Ohmichi; Takashi Kasai; Masanori Nakagawa; Toshiki Mizuno; Omar M A El-Agnaf
Journal:  PLoS One       Date:  2015-04-07       Impact factor: 3.240

Review 5.  Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease.

Authors:  Félix J Jiménez-Jiménez; Hortensia Alonso-Navarro; Elena García-Martín; José A G Agúndez
Journal:  Front Cell Neurosci       Date:  2014-11-11       Impact factor: 5.505

6.  Autoimmune antibody decline in Parkinson's disease and Multiple System Atrophy; a step towards immunotherapeutic strategies.

Authors:  Tomasz Brudek; Kristian Winge; Jonas Folke; Søren Christensen; Karina Fog; Bente Pakkenberg; Lars Østergaard Pedersen
Journal:  Mol Neurodegener       Date:  2017-06-07       Impact factor: 14.195

7.  Circulating immune complexes of Abeta and IgM in plasma of patients with Alzheimer's disease.

Authors:  Andrea Marcello; Oliver Wirths; Thomas Schneider-Axmann; Malin Degerman-Gunnarsson; Lars Lannfelt; Thomas A Bayer
Journal:  J Neural Transm (Vienna)       Date:  2009-05-05       Impact factor: 3.575

8.  α-Synuclein and anti-α-synuclein antibodies in Parkinson's disease, atypical Parkinson syndromes, REM sleep behavior disorder, and healthy controls.

Authors:  Lynnae M Smith; Mya C Schiess; Mary P Coffey; Andrea C Klaver; David A Loeffler
Journal:  PLoS One       Date:  2012-12-17       Impact factor: 3.240

9.  Epitope Mapping of Antibodies to Alpha-Synuclein in LRRK2 Mutation Carriers, Idiopathic Parkinson Disease Patients, and Healthy Controls.

Authors:  Beatriz Alvarez-Castelao; Ana Gorostidi; Javier Ruíz-Martínez; Adolfo López de Munain; José G Castaño
Journal:  Front Aging Neurosci       Date:  2014-07-15       Impact factor: 5.750

10.  Human serum antibodies against EBV latent membrane protein 1 cross-react with α-synuclein.

Authors:  John Woulfe; Madison T Gray; Munisha S Ganesh; Jaap M Middeldorp
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.